Associated Papers
560G>A (rs4986782) (R187Q) Single Nucleotide Polymorphism in Arylamine N-Acetyltransferase 1 Increases Affinity for the Aromatic Amine Carcinogens 4-Aminobiphenyl and N-Hydroxy-4-Aminobiphenyl: Implications for Cancer Risk Assessment.
Doll MA et al.
Frontiers in Pharmacology, 2022
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
Silvestri V et al.
Cancer, 2017
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E et al.
British Journal of Pharmacology, 2014
Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps.
Fu Z et al.
Carcinogenesis, 2013
Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study.
Sharma S et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2010
N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.
Hein DW
Expert Opinion on Drug Metabolism & Toxicology, 2009
Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E et al.
Toxicology, 2008
Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1.
Zhu Y et al.
The Pharmacogenomics Journal, 2008
Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer.
Suzuki H et al.
Carcinogenesis, 2008
Arylamine N-acetyltransferases: from structure to function.
Sim E et al.
Drug Metabolism Reviews, 2008
Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.
Jiao L et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007
Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma.
Mahid SS et al.
Bmc Medical Genetics, 2007
Loss of function polymorphisms in NAT1 protect against spina bifida.
Jensen LE et al.
Human Genetics, 2006
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.
Li D et al.
Carcinogenesis, 2006
TaqMan real time-polymerase chain reaction methods for determination of nucleotide polymorphisms in human N-acetyltransferase-1 (NAT1) and -2 (NAT2).
Hein DW et al.
Current Protocols in Toxicology, 2005
Restriction fragments length polymorphism in the NAT1 gene of Europeans in West Siberia.
Nikishina MV et al.
Bulletin of Experimental Biology and Medicine, 2003
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E et al.
The American Journal of Gastroenterology, 2002
Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1.
Fretland AJ et al.
Pharmacogenetics, 2001
Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population.
Sekine A et al.
Journal of Human Genetics, 2001
Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.
Lin HJ et al.
Pharmacogenetics, 1998
[Use of restriction endonucleases Bst2U I and Acc65 I to detect Kpn I polymorphism of NAT2 gene].
Nikishina MV et al.
Biomeditsinskaia Khimiia, 0
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M et al.
Lancet (london, England), 0
Fire Usage and Ancient Hominin Detoxification Genes: Protective Ancestral Variants Dominate While Additional Derived Risk Variants Appear in Modern Humans.
Aarts JM et al.
Plos One, 0